The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival

Nature

Volumn 546, Issue 7658, 2017, Pages 426-430

  Wang, Haizhen ^a,b   Nicolay, Brandon N ^c   Chick, Joel M ^b   Gao, Xueliang ^a,b   Geng, Yan ^a,b   Ren, Hong ^a,b   Gao, Hui ^d   Yang, Guizhi ^d   Williams, Juliet A ^d   Suski, Jan M ^a,b   Keibler, Mark A ^e   Sicinska, Ewa ^a   Gerdemann, Ulrike ^a   Haining, W Nicholas ^a,f,g   Roberts, Thomas M ^a,b   Polyak, Kornelia ^a   Gygi, Steven P ^b   Dyson, Nicholas J ^c   Sicinski, Piotr ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^d NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^e Massachusetts Institute of Technology Cambridge   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 PHOSPHOFRUCTOKINASE; CYCLIN D3; CYCLIN DEPENDENT KINASE 6; GLUTATHIONE; PENTOSE PHOSPHATE; PYRUVATE KINASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SERINE; AMINOPYRIDINE DERIVATIVE; CDK4 PROTEIN, HUMAN; CDK6 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE 4; PURINE DERIVATIVE; REACTIVE NITROGEN SPECIES; RIBOCICLIB;

APOPTOSIS; CANCER; CATALYSIS; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; INHIBITOR; METABOLISM; PHOSPHATE; REACTIVE OXYGEN SPECIES; RODENT; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CATALYSIS; CELL METABOLISM; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR XENOGRAFT; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; FEMALE; GLYCOLYSIS; METABOLISM; NEOPLASMS; OXIDATIVE STRESS; PATHOLOGY; PENTOSE PHOSPHATE CYCLE; PHOSPHORYLATION; TUMOR CELL LINE;

MUS;

AMINOPYRIDINES; ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN D3; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; GLYCOLYSIS; HUMANS; MICE; NEOPLASMS; OXIDATIVE STRESS; PENTOSE PHOSPHATE PATHWAY; PHOSPHOFRUCTOKINASE-1; PHOSPHORYLATION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PURINES; PYRUVATE KINASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SERINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85020944294     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature22797     Document Type: Article

References (36)

1. Malumbres, M. Cyclin-dependent kinases. Genome Biol. 15, 122 (2014).
2. Sherr, C. J., Beach, D. & Shapiro, G. I. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 6, 353-367 (2016).
3. Deshpande, A., Sicinski, P. & Hinds, P. W. Cyclins and CDKs in development and cancer: a perspective. Oncogene 24, 2909-2915 (2005).
4. Dean, J. L., Thangavel, C., McClendon, A. K., Reed, C. A. & Knudsen, E. S. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene 29, 4018-4032 (2010).
5. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010).
6. Dean, J. L. et al. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle 11, 2756-2761 (2012).
7. Choi, Y. J. et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 22, 438-451 (2012).
8. Sawai, C. M. et al. Therapeutic targeting of the cyclin D3:CDK4/6 complex in T cell leukemia. Cancer Cell 22, 452-465 (2012).
9. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
10. Christofk, H. R. et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452, 230-233 (2008).
11. Tong, X., Zhao, F. & Thompson, C. B. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. Curr. Opin. Genet. Dev. 19, 32-37 (2009).
12. Banaszak, K. et al. The crystal structures of eukaryotic phosphofructokinases from baker's yeast and rabbit skeletal muscle. J. Mol. Biol. 407, 284-297 (2011).
13. Brüser, A., Kirchberger, J., Kloos, M., Sträter, N. & Schöneberg, T. Functional linkage of adenine nucleotide binding sites in mammalian muscle 6-phosphofructokinase. J. Biol. Chem. 287, 17546-17553 (2012).
14. Schöneberg, T., Kloos, M., Brüser, A., Kirchberger, J. & Sträter, N. Structure and allosteric regulation of eukaryotic 6-phosphofructokinases. Biol. Chem. 394, 977-993 (2013).
15. Mazurek, S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969-980 (2011).
16. Anastasiou, D. et al. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science 334, 1278-1283 (2011).
17. Boada, J. et al. Cells overexpressing fructose-2, 6-bisphosphatase showed enhanced pentose phosphate pathway flux and resistance to oxidative stress. FEBS Lett. 480, 261-264 (2000).
18. Chaneton, B. et al. Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature 491, 458-462 (2012).
19. Yi, W. et al. Phosphofructokinase 1 glycosylation regulates cell growth and metabolism. Science 337, 975-980 (2012).
20. Fan, J. et al. Quantitative flux analysis reveals folate-dependent NADPH production. Nature 510, 298-302 (2014).
21. Phong, W. Y. et al. Characterization of phosphofructokinase activity in Mycobacterium tuberculosis reveals that a functional glycolytic carbon flow is necessary to limit the accumulation of toxic metabolic intermediates under hypoxia. PLoS One 8, e56037 (2013).
22. Kotlarz, D. & Buc, H. Phosphofructokinases from Escherichia coli. Methods Enzymol. 90, 60-70 (1982).
23. Cetica, P., Pintos, L., Dalvit, G. & Beconi, M. Activity of key enzymes involved in glucose and triglyceride catabolism during bovine oocyte maturation in vitro. Reproduction 124, 675-681 (2002).
24. Divita, G., Goody, R. S., Gautheron, D. C. & Di Pietro, A. Structural mapping of catalytic site with respect to alpha-subunit and noncatalytic site in yeast mitochondrial F1-ATPase using fluorescence resonance energy transfer. J. Biol. Chem. 268, 13178-13186 (1993).
25. Vertommen, D. et al. The ATP-binding site in the 2-kinase domain of liver 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase. Study of the role of Lys-54 and Thr-55 by site-directed mutagenesis. J. Biol. Chem. 271, 17875-17880 (1996).
26. Nicolay, B. N. et al. Loss of RBF1 changes glutamine catabolism. Genes Dev. 27, 182-196 (2013).
27. Antoniewicz, M. R., Kelleher, J. K. & Stephanopoulos, G. Determination of confidence intervals of metabolic fluxes estimated from stable isotope measurements. Metab. Eng. 8, 324-337 (2006).
28. Antoniewicz, M. R., Kelleher, J. K. & Stephanopoulos, G. Elementary metabolite units (EMU): a novel framework for modeling isotopic distributions. Metab. Eng. 9, 68-86 (2007).
29. Yoo, H., Antoniewicz, M. R., Stephanopoulos, G. & Kelleher, J. K. Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line. J. Biol. Chem. 283, 20621-20627 (2008).
30. Young, J. D., Walther, J. L., Antoniewicz, M. R., Yoo, H. & Stephanopoulos, G. An elementary metabolite unit (EMU) based method of isotopically nonstationary flux analysis. Biotechnol. Bioeng. 99, 686-699 (2008).
31. Marin-Valencia, I. et al. Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed. 25, 1177-1186 (2012).
32. Huttlin, E. L. et al. A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-1189 (2010).
33. Eng, J. K., McCormack, A. L. & Yates, J. R. An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database. J. Am. Soc. Mass Spectrom. 5, 976-989 (1994).
34. Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207-214 (2007).
35. Beausoleil, S. A., Villén, J., Gerber, S. A., Rush, J. & Gygi, S. P. A probabilitybased approach for high-throughput protein phosphorylation analysis and site localization. Nat. Biotechnol. 24, 1285-1292 (2006).
36. Gao, H. et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat. Med. 21, 1318-1325 (2015).